Alterations of dendritic cell subsets in the peripheral circulation of patients with cervical carcinoma

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Ye, Feng ^a   Yu, Yan ^a   Hu, Yuting ^a   Lu, Weiguo ^a   Xie, Xing ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD123 ANTIGEN; CD86 ANTIGEN; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; CYTOKINE;

ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX TUMOR;

CASE-CONTROL STUDIES; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTOKINES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; PROGNOSIS; UTERINE CERVICAL NEOPLASMS;

EID: 77953641687     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-78     Document Type: Article

References (45)

1. Estimates of the worldwide mortality from 25 cancers in 1990. P Pisani DM Parkin F Bray J Ferlay, International journal of cancer 1999 83 18 29 10.1002/(SICI)1097-0215(19990924)83:1<18::AID-IJC5>3.0.CO;2-M (Pubitemid 29409471)
2. Risk assessment to guide the prevention of cervical cancer. PE Castle M Sideri J Jeronimo D Solomon M Schiffman, American journal of obstetrics and gynecology 2007 197 356 1 6 17904958
3. The causal relation between human papillomavirus and cervical cancer. FX Bosch A Lorincz N Munoz CJ Meijer KV Shah, Journal of clinical pathology 2002 244 65
4. Inhibition of tumor growth by elimination of granulocytes. LA Pekarek BA Starr AY Toledano H Schreiber, The Journal of experimental medicine 1995 181 435 40
5. Cervical cancer vaccines: progress and prospects. MA Steller, Journal of the Society for Gynecologic Investigation 2002 9 254 64 10.1016/S1071-5576(02) 00166-1 12383909
6. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. L Muderspach S Wilczynski L Roman, et al. Clin Cancer Res 2000 6 3406 16 10999722
7. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. F Landoni A Maneo A Colombo, et al. Lancet 1997 350 535 40 10.1016/S0140-6736(97)02250-2 9284774
8. Management of metastatic cervical cancer: review of the literature. HJ Long, J Clin Oncol 2007 25 2966 74 10.1200/JCO.2006.09.3781 17617528
9. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. MH Stoler CR Rhodes A Whitbeck SM Wolinsky LT Chow TR Broker, Human pathology 1992 23 117 28 10.1016/0046-8177(92)90232-R 1310950
10. Biological-clinical significance of selective loss of HLA-class-I allelic product expression in squamous-cell carcinoma of the uterine cervix. S Honma S Tsukada S Honda, et al. International journal of cancer 1994 57 650 5 10.1002/ijc.2910570507 (Pubitemid 24201354)
11. Immunological functions of non-professional antigen-presenting cells: new insights from studies of T-cell interactions with keratinocytes. BJ Nickoloff LA Turka, Immunology today 1994 15 464 9 10.1016/0167-5699(94)90190-2 7945770
12. The dendritic cell system and its role in immunogenicity. RM Steinman, Annual review of immunology 1991 9 271 96 10.1146/annurev.iy.09.040191.001415 1910679
13. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). M Adams H Navabi B Jasani, et al. Vaccine 2003 21 787 90 10.1016/S0264-410X(02)00599-6 12531360
14. Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. AD Santin S Bellone JJ Roman A Burnett MJ Cannon S Pecorelli, Current pharmaceutical design 2005 11 3485 500 10.2174/138161205774414565 16248803
15. Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector. Y Liu M Chiriva-Internati F Grizzi, et al. Cancer gene therapy 2001 8 948 57 10.1038/sj.cgt.7700391 11781657
16. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. AD Santin S Bellone M Palmieri, et al. Gynecologic oncology 2006 100 469 78 10.1016/j.ygyno.2005.09.040 16249018
17. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. A Ferrara M Nonn P Sehr, et al. Journal of cancer research and clinical oncology 2003 129 521 30 10.1007/s00432-003-0463-5 12898233
18. Human dendritic cell subsets for vaccination. P Dubsky H Ueno B Piqueras J Connolly J Banchereau AK Palucka, Journal of clinical immunology 2005 25 551 72 10.1007/s10875-005-8216-7 16380819
19. Regulation of the lifespan in dendritic cell subsets. M Chen L Huang Z Shabier J Wang, Molecular immunology 2007 44 2558 65 10.1016/j.molimm.2006.12. 020 17267035
20. Differential antigen processing by dendritic cell subsets in vivo. D Dudziak AO Kamphorst GF Heidkamp, et al. Science (New York, NY) 2007 315 107 11
21. Plasmacytoid dendritic cells in immunity. M Colonna G Trinchieri YJ Liu, Nature immunology 2004 5 1219 26 10.1038/ni1141 15549123
22. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. N Kadowaki S Ho S Antonenko, et al. The Journal of experimental medicine 2001 194 863 9 10.1084/jem.194.6.863 11561001
23. Dendritic cells in peripheral blood of patients with breast and lung cancer - a pilot study. K Wojas J Tabarkiewicz M Jankiewicz J Rolinski, Folia histochemica et cytobiologica/Polish Academy of Sciences, Polish Histochemical and Cytochemical Society 2004 42 45 8 15046400
24. Flow cytometric analysis of circulating dendritic cell subsets and intracellular cytokine production in advanced breast cancer patients. S Ferrari F Malugani B Rovati C Porta A Riccardi M Danova, Oncology reports 2005 14 113 20 15944777
25. Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients. B Maecker D Mougiakakos M Zimmermann, et al. Leukemia 2006 20 645 9 10.1038/sj.leu.2404146 16498391
26. Pretreatment plasma TGF beta 1 levels are prognostic for survival but not morbidity following radiation therapy of carcinoma of the cervix. J Dickson SE Davidson RD Hunter CM West, International journal of radiation oncology, biology, physics 2000 48 991 5 10.1016/S0360-3016(00)00729-X 11072155
27. Dendritic cells are functionally defective in multiple myeloma the role of interleukin-6. M Ratta F Fagnoni A Curti, et al. Blood 2002 100 230 7 10.1182/blood.V100.1.230 12070032
28. Modulation of tight junction structure and function by cytokines. SV Walsh AM Hopkins A Nusrat, Advanced drug delivery reviews 2000 41 303 13 10.1016/S0169-409X(00)00048-X 10854688
29. Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. S Beckebaum X Zhang X Chen, et al. Clin Cancer Res 2004 10 7260 9 10.1158/1078-0432.CCR-04-0872 15534100
30. Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. T Saito G Dworacki W Gooding MT Lotze TL Whiteside, Clin Cancer Res 2000 6 1351 64 10778963
31. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. TJ Curiel G Coukos L Zou, et al. Nature medicine 2004 10 942 9 10.1038/nm1093 15322536
32. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. CC Sombroek AG Stam AJ Masterson, et al. J Immunol 2002 168 4333 43 11970975
33. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. S Della Bella M Gennaro M Vaccari, et al. British journal of cancer 2003 89 1463 72 10.1038/sj.bjc.6601243 14562018
34. Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease. P Lissoni L Vigore R Ferranti, et al. Journal of biological regulators and homeostatic agents 1999 13 216 9 10703945
35. Increased serum transforming growth factor-beta1 in human colorectal cancer correlates with reduced circulating dendritic cells and increased colonic Langerhans cell infiltration. A Huang JW Gilmour N Imami P Amjadi DC Henderson TG Allen-Mersh, Clinical and experimental immunology 2003 134 270 8 10.1046/j.1365-2249.2003.02295.x 14616787
36. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. TK Hoffmann J Muller-Berghaus RL Ferris JT Johnson WJ Storkus TL Whiteside, Clin Cancer Res 2002 8 1787 93 12060618
37. Dendritic cell-based immunotherapy of malignant melanoma: success and limitations. A Tuettenberg E Schmitt J Knop H Jonuleit, J Dtsch Dermatol Ges 2007 5 190 6 10.1111/j.1610-0387.2007.06179.x 17338793
38. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. UK Liyanage TT Moore HG Joo, et al. J Immunol 2002 169 2756 61 12193750
39. Deficiencies in myeloid antigen-presenting cells in women with cervical squamous intraepithelial lesions. BN Lee M Follen G Rodriquez, et al. Cancer 2006 107 999 1007 10.1002/cncr.22092 16874820
40. Plasmacytoid dendritic cells - virus experts of innate immunity. W Barchet M Cella M Colonna, Seminars in immunology 2005 17 253 61 10.1016/j.smim.2005.05.008 15990333
41. Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. M Della Porta M Danova GM Rigolin, et al. Oncology 2005 68 276 84 10.1159/000086784 16015045
42. Mechanisms and functional significance of tumour-induced dendritic-cell defects. D Gabrilovich, Nature reviews 2004 4 941 52 10.1038/nri1498 15573129
43. Analysis of host versus tumor interaction in cancer patients: opposing role of transforming growth factor-beta1 and interleukin-6 in the development of in situ tumor immunity. JP Tsai HW Chen ML Cheng, et al. Immunobiology 2005 210 661 71 10.1016/j.imbio.2005.07.004 16323703
44. Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. G Bellone A Carbone C Smirne, et al. J Immunol 2006 177 3448 60 16920987
45. Decreased antigen presentation by dendritic cells in patients with breast cancer. DI Gabrilovich J Corak IF Ciernik D Kavanaugh DP Carbone, Clin Cancer Res 1997 3 483 90 9815709